Cerebain Biotech Corp. (CBBT) 0.8000 $CBBT
Cerebain Biotech to sell up to 1.6m shares of its stock to GMEA
M2 - Tue Jun 09, 5:45AM CDT
Medical device company Cerebain Biotech (OTCBB:CBBT) disclosed on Monday that it has entered into an agreement to sell up to 1,600,000 shares of its stock to GMEA (Geronimo Middle East and Africa).
Cerebain Biotech Receives Financial Commitment of Two Million Dollars
Business Wire - Mon Jun 08, 7:30AM CDT
Cerebain Biotech (OTCQB: CBBT) today announced that the company has executed an agreement with GMEA (Geronimo Middle East and Africa) to purchase up to One Million Six Hundred Thousand (1,600,000) shares of the company's stock. These funds will be used to support financial and business development goals that will help the company accelerate its research and testing programs, currently focused on the development of a new treatment in the fight against Alzheimer's Disease.
Cerebain Biotech Appoints Mustafa Husain, M.D., to Scientific Advisory Board
Business Wire - Thu Jan 29, 6:30AM CST
Cerebain Biotech (OTCQB: CBBT) today announced that the company has appointed Mustafa Husain, M.D., to its Scientific Advisory Board. Dr. Husain is a preeminent researcher with expertise in device-based research for Neuropsychiatric Disorders.
Scott McCallum, Former Wisconsin Governor, Engaged by Cerebain Biotech as Special Advisor
Business Wire - Thu Dec 04, 6:30AM CST
Cerebain Biotech (OTCQB: CBBT) today announced that the company has engaged Scott McCallum, former governor of Wisconsin, entrepreneur and present Counsel on International Government to Hamilton Advisors, as a special advisor. Cerebain is an early-stage research and development company focused on evaluating a novel approach to the treatment of Alzheimer's Disease. Governor McCallum will serve as an invaluable resource in supporting rapid growth for the company as omental stimulation, the focus of Cerebain's research, is formally launched for study in Europe and then the United States.
Cerebain Biotech Engages Miriam Weber Miller, Industry Veteran, as Corporate Vice President
Business Wire - Mon Sep 22, 8:00AM CDT
Cerebain Biotech (OTCBB: CBBT) today announced that the company has engaged biotech industry veteran Miriam Weber Miller to serve on the executive team, as corporate vice president, reporting to CEO Eric Clemons. The appointment comes as Cerebain readies itself for clinical trials in Europe for the evaluation of a new approach to Alzheimer's treatment. Weber Miller will work cross-functionally, driving business development, and growth strategies communication and investor relations. She will also serve as a corporate spokesperson.
Cerebain Biotech to sell up to 1.6m shares of its stock to GMEA
M2 - Tue Jun 09, 5:45AM CDT
Medical device company Cerebain Biotech (OTCBB:CBBT) disclosed on Monday that it has entered into an agreement to sell up to 1,600,000 shares of its stock to GMEA (Geronimo Middle East and Africa).
Cerebain Biotech Receives Financial Commitment of Two Million Dollars
Business Wire - Mon Jun 08, 7:30AM CDT
Cerebain Biotech (OTCQB: CBBT) today announced that the company has executed an agreement with GMEA (Geronimo Middle East and Africa) to purchase up to One Million Six Hundred Thousand (1,600,000) shares of the company's stock. These funds will be used to support financial and business development goals that will help the company accelerate its research and testing programs, currently focused on the development of a new treatment in the fight against Alzheimer's Disease.
Cerebain Biotech Appoints Mustafa Husain, M.D., to Scientific Advisory Board
Business Wire - Thu Jan 29, 6:30AM CST
Cerebain Biotech (OTCQB: CBBT) today announced that the company has appointed Mustafa Husain, M.D., to its Scientific Advisory Board. Dr. Husain is a preeminent researcher with expertise in device-based research for Neuropsychiatric Disorders.
Scott McCallum, Former Wisconsin Governor, Engaged by Cerebain Biotech as Special Advisor
Business Wire - Thu Dec 04, 6:30AM CST
Cerebain Biotech (OTCQB: CBBT) today announced that the company has engaged Scott McCallum, former governor of Wisconsin, entrepreneur and present Counsel on International Government to Hamilton Advisors, as a special advisor. Cerebain is an early-stage research and development company focused on evaluating a novel approach to the treatment of Alzheimer's Disease. Governor McCallum will serve as an invaluable resource in supporting rapid growth for the company as omental stimulation, the focus of Cerebain's research, is formally launched for study in Europe and then the United States.
Cerebain Biotech Engages Miriam Weber Miller, Industry Veteran, as Corporate Vice President
Business Wire - Mon Sep 22, 8:00AM CDT
Cerebain Biotech (OTCBB: CBBT) today announced that the company has engaged biotech industry veteran Miriam Weber Miller to serve on the executive team, as corporate vice president, reporting to CEO Eric Clemons. The appointment comes as Cerebain readies itself for clinical trials in Europe for the evaluation of a new approach to Alzheimer's treatment. Weber Miller will work cross-functionally, driving business development, and growth strategies communication and investor relations. She will also serve as a corporate spokesperson.
